Kim G. Johnson, MD

Articles by Kim G. Johnson, MD

Sandi See Tai, MD, chief development officer at Lexeo

Gene Therapy for APOE4 Homozygous Alzheimer Disease

ByKim G. Johnson, MD,R. Nolan Townsend,Sandi See Tai, MD,Isabella Ciccone, MPH,Noah Stansfield

November 6th 2024

R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.

R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD

R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease

ByKim G. Johnson, MD,R. Nolan Townsend,Sandi See Tai, MD,Isabella Ciccone, MPH

October 31st 2024

The 3 experts discussed Lexeo Therapeutics’ LX1001 gene therapy trial that demonstrated promising safety and biomarker effects in patients with early-stage Alzheimer disease.

Kim G. Johnson, MD

Articles by Kim G. Johnson, MD

Gene Therapy for APOE4 Homozygous Alzheimer Disease

R. Nolan Townsend, Sandi See Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozygous Alzheimer Disease

Latest Updated Articles

Trending on CGTlive®

Myrtelle’s Canavan Disease Gene Therapy Effects Significant Decrease in CSF NAA and Increases in Brain Myelin Volume